USPSTF Recommendation: Medications to Reduce Risk of Breast Cancer

This 2019 Recommendation Statement from the US Preventive Services Task Force recommends that clinicians offer tamoxifen, raloxifene, or aromatase inhibitors to women at increased risk for breast cancer and at low risk for adverse medication effects (B recommendation) and recommends against routine use of such medications in women not at increased risk for breast cancer (D recommendation).
Source: JAMA - Category: General Medicine Source Type: research